Description
Product Usage Information
NSC-95397 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.61 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
NSC-95397 is a quinone-containing inhibitor of the cdc25 dual-specificity phosphatases responsible for regulating eukaryotic cell entry into mitosis. The primary substrate of cdc25A is CDK2, which allows progression through the G1/S and intra-S checkpoints; cdc25C activates CDK1 to overcome the G2/M checkpoint and allow mitotic entry (1). cdc25 phosphatase inhibition by NSC-95397 varies, with dissociation constants for cdc25A, -B, and -C of Ki = 32 nM, 96 nM, and 40 nM, respectively (2). NSC-95397 treatment of cancer cell lines leads to cell growth inhibition and cell cycle arrest at G2/M (1). Similar growth inhibition was seen in human hepatoma and breast cancer cells (3). Exposure of human erythrocytes to NSC-95397 triggers cell shrinkage, cell membrane scrambling, and eryptosis (4). The dual-specificity phosphatases MAP Kinase phosphatase 1 (MKP1) and MKP3 are likewise inhibited by NSC-95397, with NSC-95397 treatment followed by inhibited proliferation and reduced cell viability in a number of colon cancer cell lines (5,6).
Alternate Names
2,3-bis[(2-Hydroxyethyl)thiol]-1,4-naphthoquinone
